Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12067290 | 1.00 | MAPT (0.33) | MAPTSMN1; SMN2NPC1PKMNFKB1 | |
| SCHEMBL14745936 | 1.00 | MAPT (0.33) | MAPTSMN1; SMN2NPC1PKMNFKB1 | |
| SCHEMBL14791071 | 0.79 | MAPT (0.37) | MAPTSMN1; SMN2NPC1PKMNFKB1 | |
| SCHEMBL1966568 | 0.71 | NR1H2 (0.39) | MAPTSMN1; SMN2NPC1PKMNFKB1 | |
| SCHEMBL14794964 | 0.69 | KDM4E (0.37) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1968376 | 0.68 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2NPC1NFKB1RAB9A | |
| SCHEMBL519468 | 0.67 | ALDH1A1 (0.52) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL15771663 | 0.64 | KDM4E (0.39) | MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL15771661 | 0.64 | KDM4E (0.39) | MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL866607 | 0.64 | RAB9A (0.58) | MAPTSMN1; SMN2NPC1PKMNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576561-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013033093-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | MAPT 4366/4885SMN1; SMN2 4086/4885NPC1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.